New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

UCB-Lennox-Gastaut

More Like This

EpilepsyGTx announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201

Novotech Report Analyses Epilepsy Research Trends Finding More than 4,000 Clinical Trials Conducted Globally

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Figure 1. Work Productivity: Absenteeism, presenteeism, overall work productivity loss and activity impairment: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls are marked with asterisks. Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay. Absenteeism was not calculated for those who worked 0 hours and missed 0 hours in the last 7 days, and presenteeism was only asked among those who worked >0 hours in the last 7 days. (Abbreviations: GAD: generalized anxiety disorder.) (Graphic: Business Wire)

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

PR Newswire associated0

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024